John W Danaher MD

CIK 1309445 · View on SEC EDGAR ↗

Insider

First SEC filing: Sept. 21, 2021 · Latest: Sept. 21, 2021

On this page

Insider at

Insider transactions

0 buys (P) 0 sells (S) Net: $0 + 4 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

No open-market trades on record; showing all filings.

Date Ticker Code Shares Price Value Owned after Δ own A/D vs now
Aug. 25, 2023 CVSA F 2,949 $43.20 $127,397 38,718 Direct -7.08% Disposed 195.9% (price as of 2026-08-21)
Aug. 24, 2023 CVSA F 419 $43.47 $18,214 41,667 Direct -1.00% Disposed 194.0% (price as of 2026-08-21)
Aug. 25, 2022 CVSA F 2,934 $41.12 $120,646 42,086 Direct -6.52% Disposed 210.8% (price as of 2026-08-21)
Aug. 24, 2022 CVSA A 4,420 $39.74 $175,651 45,020 Direct +10.89% Acquired 221.6% (price as of 2026-08-21)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Initial ownership (Form 3) 2 holdings

Securities held when first becoming an insider, per SEC Form 3.

Date Ticker Security Shares Ownership
Sept. 21, 2021 CVSA Common Stock [F1] 40,600 Direct
Sept. 21, 2021 CVSA Incentive Stock Option (Right to Buy) [F2]→ Common Stock (8,275) 8,275 Direct

Compensation (DEF 14A)

Matched by name from proxy statements (DEF 14A) — verify against the filing.

CVSA

President, Medical and Veterinary
Fiscal year Salary Bonus Stock awards Option awards Non-equity incentive Pension change Other Total
2022 $472,500 $275,000 — — $115,513 — $17,766 $2,780,947

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.